Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06724614 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of VDPHL01 in Males With AGA

A Phase 2 study of Androgenetic Alopecia and AGA, sponsored by Veradermics.

Active
Registry status
Phase 2
Development phase
480
Enrollment target
20
Study locations

NCT06724614 is a Phase 2 study of Androgenetic Alopecia and AGA that is active but no longer recruiting, run by Veradermics. The registered enrollment target is 480 participants, above the 135-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (256% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06724614, a Phase 2 study of Androgenetic Alopecia and AGA, is active but no longer recruiting, sponsored by Veradermics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
480 participants
Enrollment target
20
Study locations

Study Summary

This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). The first 7 visits will be part of the placebo-controlled period. The next 3 visits will be part of the treatment extension phase. All subjects will receive active drug in the treatment extension phase.

Conditions Studied

Androgenetic Alopecia AGA Male Pattern Baldness

Interventions

  • DRUG Placebo
  • DRUG VDPHL01

Study Locations (20)

California

  • Site 07 - Fountain Valley
  • Site 02 - Fremont
  • Site 34 - Sherman Oaks
  • Site 21 - Vista

Florida

  • Site 17 - Aventura
  • Site 25 - Brandon
  • Site 42 - Hollywood
  • Site 03 - Tampa

Indiana

  • Site 15 - Indianapolis
  • Site 32 - New Albany
  • Site 27 - West Lafayette

Arkansas

  • Site 30 - Fort Smith
  • Site 35 - Rogers

Colorado

  • Site 05 - Castle Rock
  • Site 24 - Englewood

Alabama

  • Site 36 - Birmingham

Arizona

  • Site 28 - Phoenix

Georgia

  • Site 43 - Atlanta

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2024-11-06
Est. Completion 2026-09
Phase Phase 2

Sponsor

Veradermics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06724614

The ClinicalTrials.gov registry entry for NCT06724614 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 135-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (256% higher). The listed sponsor is Veradermics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Androgenetic Alopecia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06724614 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Indiana.

Frequently Asked Questions

What is clinical trial NCT06724614 about?

NCT06724614 is a clinical study titled "Efficacy and Safety of VDPHL01 in Males With AGA". This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an inve...

What is the current status of trial NCT06724614?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2024-11-06. Estimated completion is 2026-09.

What conditions does trial NCT06724614 study?

This clinical trial studies the following conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness.

What interventions are being tested in trial NCT06724614?

The interventions under investigation include: Placebo (DRUG), VDPHL01 (DRUG).

Who is sponsoring clinical trial NCT06724614?

This trial is sponsored by Veradermics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06724614 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Androgenetic Alopecia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Androgenetic Alopecia

All registered trials for this condition

AGA

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.